Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 3/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513456 | 1.00 | SLC40A1 (0.44) | SLC40A1GLO1PIK3CAMTORCACNA1B | |
| SCHEMBL29970032 | 0.90 | CACNA1B (0.51) | SLC40A1PIK3CAMTORCACNA1BCACNA1H | |
| SCHEMBL29969100 | 0.88 | CACNA1B (0.41) | CACNA1BCACNA1HHTTSMN1; SMN2 | |
| SCHEMBL21513773 | 0.88 | CACNA1B (0.41) | CACNA1BCACNA1HHTTSMN1; SMN2 | |
| SCHEMBL29969654 | 0.87 | CACNA1B (0.47) | SLC40A1PIK3CACACNA1BCACNA1HTSHR | |
| SCHEMBL26130327 | 0.87 | CACNA1B (0.47) | SLC40A1PIK3CACACNA1BCACNA1HTSHR | |
| SCHEMBL21513762 | 0.85 | ALDH1A1 (0.48) | CACNA1BCACNA1HHTTSMN1; SMN2 | |
| SCHEMBL29968192 | 0.85 | ALDH1A1 (0.48) | CACNA1BCACNA1HHTTSMN1; SMN2 | |
| SCHEMBL21512855 | 0.85 | KEAP1 (0.47) | SLC40A1GLO1CACNA1BCACNA1HKEAP1 | |
| SCHEMBL29968164 | 0.85 | KEAP1 (0.47) | SLC40A1GLO1CACNA1BCACNA1HKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | SLC40A1 4123/4885GLO1 4474/4885PIK3CA 480/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | SLC40A1 4123/4885GLO1 4474/4885PIK3CA 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.